These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 9723264)
1. Safety and efficacy of conversion from once daily Sandimmun to twice daily Neoral cyclosporine in renal allograft recipients. Vathsala A; Lee WT; Lu YM; Woo KT Transplant Proc; 1998 Aug; 30(5):1746-8. PubMed ID: 9723264 [No Abstract] [Full Text] [Related]
2. Cyclosporine pharmacokinetic profiles in stable renal allograft recipients converting from Sandimmun to Neoral. Vathsala A; Lee WT; Jacob E; Woo KT Transplant Proc; 1996 Jun; 28(3):1324-6. PubMed ID: 8658678 [No Abstract] [Full Text] [Related]
4. Pharmacokinetic study of twice vs thrice daily dosing of Sandimmun Neoral in pediatric renal transplant patients. Papachristou F; Gakis D; Sotiriou I; Liatsis I; Takoudas D; Antoniadis A Transplant Proc; 1998 Aug; 30(5):1988-90. PubMed ID: 9723363 [No Abstract] [Full Text] [Related]
5. Abbreviated kinetic profiles to estimate exposure to CyA in renal allograft recipients treated with Sandimmun-Neoral. Serafinowicz A; Gaciong Z; Majchrzak J; Baczkowska T; Nowacka E; Gradowska L; Rowiński W; Lao M Transplant Proc; 1997; 29(1-2):277-9. PubMed ID: 9122994 [No Abstract] [Full Text] [Related]
6. Conversion of stable renal transplant recipients from Sandimmune to Sang-35, a Neoral-equivalent cyclosporine formulation, using a dose-adjusted method. First MR; Weiskittel P; Shah M; Peddi VR; Canafax D; Schroeder TJ Transplant Proc; 1998 Dec; 30(8):3955-7. PubMed ID: 9865260 [No Abstract] [Full Text] [Related]
7. Conversion from Sandimmune to Neoral in patients with stable renal allograft function: UHKL experience. Goh BL; Jalil R; Koh SN; Chua CT; Tan SY Transplant Proc; 1998 Nov; 30(7):3535-6. PubMed ID: 9838548 [No Abstract] [Full Text] [Related]
8. Conversion to cyclosporine microemulsion (Neoral) in stable renal transplant patients: results from a single center. Cossu M; Satta R; Branca GF; Pala PG; Serra G; Satta RP; Sorba G Transplant Proc; 1998 Aug; 30(5):1762-3. PubMed ID: 9723271 [No Abstract] [Full Text] [Related]
9. Sandimmun-to-Neoral conversion in stable pediatric kidney transplant recipients. Kelles A; Herman J; Tjandra-Maga TB; Van Damme-Lombaerts R Transplant Proc; 1998 Aug; 30(5):1995-6. PubMed ID: 9723366 [No Abstract] [Full Text] [Related]
10. Sandimmun and Neoral treatment: pharmacokinetics and kidney function in paediatric and adolescent renal transplant. De Palma MT; Giordano M; Colella V; Palumbo F; De Nicolo VE; Caringella DA Transplant Proc; 1998 Aug; 30(5):1677. PubMed ID: 9723239 [No Abstract] [Full Text] [Related]
11. Safety, tolerability, and pharmacokinetics of Sandimmun Neoral: conversion study in stable renal transplant recipients. Tsang WK; Ho YW; Tong KL; Chan WH; Chan A Transplant Proc; 1996 Jun; 28(3):1330-2. PubMed ID: 8658681 [No Abstract] [Full Text] [Related]
12. Safety and tolerability of a new oral formulation of cyclosporin A, Sandimmun Neoral, in renal transplant patients. Taesch S; Niese D Transpl Int; 1994; 7 Suppl 1():S263-6. PubMed ID: 11271220 [TBL] [Abstract][Full Text] [Related]